Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Purchases 100,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The shares were acquired at an average price of $1.27 per share, for a total transaction of $127,000.00. Following the transaction, the chief executive officer now directly owns 211,232,222 shares in the company, valued at $268,264,921.94. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, May 17th, Phillip Md Et Al Frost acquired 163,997 shares of OPKO Health stock. The shares were bought at an average price of $1.29 per share, with a total value of $211,556.13.
• On Monday, March 18th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The stock was bought at an average price of $0.87 per share, for a total transaction of $435,000.00.
• On Thursday, March 14th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were bought at an average price of $0.89 per share, with a total value of $445,000.00.
• On Tuesday, March 12th, Phillip Md Et Al Frost purchased 600,000 shares of OPKO Health stock. The stock was bought at an average cost of $0.93 per share, for a total transaction of $558,000.00.
• On Wednesday, February 28th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $0.99 per share, with a total value of $495,000.00.

OPKO Health Price Performance

NASDAQ:OPK opened at $1.36 on Friday. OPKO Health, Inc. has a one year low of $0.85 and a one year high of $2.24. The stock has a market cap of $947.91 million, a PE ratio of -3.89 and a beta of 1.81. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.62 and a current ratio of 1.91. The stock has a 50 day moving average price of $1.23 and a 200 day moving average price of $1.22.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). OPKO Health had a negative return on equity of 17.89% and a negative net margin of 31.44%. The company had revenue of $173.70 million during the quarter, compared to analyst estimates of $182.99 million. During the same period last year, the business earned ($0.02) earnings per share. The firm’s revenue was down 26.9% compared to the same quarter last year. Equities research analysts expect that OPKO Health, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OPK has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Wednesday, May 8th. Barrington Research reaffirmed an “outperform” rating and set a $1.50 target price on shares of OPKO Health in a research note on Monday, April 1st. StockNews.com upgraded shares of OPKO Health to a “sell” rating in a research report on Friday. Finally, Piper Sandler restated an “overweight” rating and set a $5.00 price target on shares of OPKO Health in a research report on Monday, April 1st.

Institutional Investors Weigh In On OPKO Health

A number of hedge funds have recently modified their holdings of the company. IPG Investment Advisors LLC purchased a new position in OPKO Health during the fourth quarter worth about $30,000. Virtu Financial LLC purchased a new stake in shares of OPKO Health during the 1st quarter valued at approximately $26,000. River Wealth Advisors LLC acquired a new position in OPKO Health in the third quarter valued at approximately $38,000. SlateStone Wealth LLC purchased a new position in OPKO Health in the first quarter worth approximately $31,000. Finally, Northstar Group Inc. acquired a new stake in OPKO Health during the fourth quarter worth $42,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.